garadacimab-gxii (Andembry)
garadacimab-gxii is an FDA-licensed reference biologic from CSL Behring LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Andembry garadacimab-gxii
CSL Behring LLC
- Approved
- Jun 16, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for garadacimab-gxii from the RCSB Protein Data Bank (PDB 8R8D).
Interactive biological assembly from PDB entry 8R8D. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for garadacimab-gxii, in chronological order.
Reference approval
Approval date of the reference garadacimab-gxii product.
1 yr ago
Frequently asked questions
Are there biosimilars approved for garadacimab-gxii (Andembry)?
No 351(k) biosimilars or interchangeable biosimilars referencing garadacimab-gxii are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.